Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Edwards Lifesciences logoEdwards Lifesciences EW

Edwards said it completed the sale of its Critical Care product group to Becton, Dickinson and Company on September 3, 2024 in an all-cash transaction valued at $4.2 billion.

8-KRegulation FD DisclosureFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Edwards said it completed the sale of its Critical Care product group to Becton, Dickinson and Company on September 3, 2024 in an all-cash transaction valued at $4.2 billion.

  2. The company said it will use the net proceeds from the sale to fund strategic initiatives, including the previously announced acquisitions and share repurchases.

  3. Edwards said its Board of Directors approved an additional $1.5 billion share repurchase authorization, and that after this $1 billion repurchase, remaining authorization for future buybacks stands at $1.4 billion.

  4. The company said it recently entered into an Accelerated Share Repurchase agreement of $500 million and repurchased $500 million of common stock in August through a 10b5-1 agreement and open market purchases.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Edwards Completes Sale of Critical Care

Edwards said it completed the sale of its Critical Care product group to Becton, Dickinson and Company on September 3, 2024 in an all-cash transaction valued at $4.2 billion.

Source · Based on the filing body and exhibits

Plans for Use of Net Proceeds from Sale

The company said it will use the net proceeds from the sale to fund strategic initiatives, including the previously announced acquisitions and share repurchases.

Source · Based on the filing body and exhibits

Additional Share Repurchase Authorization $1.5 billion

Edwards said its Board of Directors approved an additional $1.5 billion share repurchase authorization, and that after this $1 billion repurchase, remaining authorization for future buybacks stands at $1.4 billion.

Source · Based on the filing body and exhibits

$500 million Accelerated Share Repurchase Agreement and Share Repurchases in August

The company said it recently entered into an Accelerated Share Repurchase agreement of $500 million and repurchased $500 million of common stock in August through a 10b5-1 agreement and open market purchases.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.